Microbiome Platform Articles & Analysis: Older
20 news found
--(BUSINESS WIRE)--May 4, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. ...
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis ...
ByBio-Me
The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). ...
Both MB097 and MB310 are precision medicines derived by highly accurate clinical microbiome profiling using Microbiotica’s platform which links consortia of bacteria with clinical trial outcome data. ...
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer ...
In addition, the funds will be used to drive forward the company’s drug discovery programs based on the company’s platform in the microbiome gut-brain axis. Axial is advancing a pipeline of small molecule drugs with defined mechanisms of action that act on new targets to mitigate the impact of metabolites and bacteria in the gut linked to neurological ...
However clinical translation of this ground-breaking discovery has been hampered by large inconsistencies between studies in the intestinal bacteria associated with anti-PD1 efficacy. The Microbiotica platform is unrivalled in the comprehensiveness and precision by which it can profile the microbiome of patients. ...
However clinical translation of this ground-breaking discovery has been hampered by large inconsistencies between studies in the intestinal bacteria associated with anti-PD1 efficacy. The Microbiotica platform is unrivalled in the comprehensiveness and precision by which it can profile the microbiome of patients. ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has finalised its move to purpose-configured facilities at Chesterford Research Park, to accommodate its long-term growth requirements. ...
These technologies are effective for single microbes, complex microbial consortia and whole microbiome products, and are integrated with a computational AI platform, which enables the design of unique microbial consortia and whole microbiome profiles. ...
Microbiome Dx company Bio-Me and Siolta Therapeutics today announced that they have entered into a collaboration and marketing agreement. ...
ByBio-Me
Microbiome Dx company Bio-Me and Siolta Therapeutics today announced that they have entered into a collaboration and marketing agreement. ...
” In addition to SeylanMED’s topical AKT inhibitor gel for the treatment of SKs, DermBiont plans to initiate least four other phase 2b clinical trials in 2021 with live bacterial therapeutics discovered internally from its microbiome platform technology. “We are rapidly advancing proprietary, first-in-class, targeted topical drug candidates ...
Notitia Biotechnologies Company has received the Investigational New Drug (IND) approval from the FDA for NBT-NM108, a proprietary formula designed to support the Foundation Guild bacteria in the patient's gut microbiome. The FDA has allowed Notitia to test the drug as a treatment for COVID-19 in patients with type 2 diabetes and prediabetes. ...
The drug, NBT-BM306, combines the purified Foundation Guild bacteria and the tailored microbiome nutrition to support their growth in one convenient format. ...
Under a National Institute of Health (NIH) grant awarded by the National Institute of General Medical Sciences (NIGMS), Microvi, Nexilico, and their research partners have developed a first-of-its-kind predictive computational platform focused on the gut microbiome and its interaction with therapeutics. ...
MedBiome’s founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into ...
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. ...
Bio-Me, a pioneer in rapid gut microbiome analysis is announcing the opening of its gut microbiome analysis service laboratory. This will enable the Research & Development departments worldwide to access their Precision Microbiome Profiling (PMP™) platform. The service laboratory is located at the Oslo’s Science ...
ByBio-Me